fashion -WSS

fashion

author：knowledge 2025-10-01 11:46:51 - browse：26

a doctor wraps a smart watch around a patient's wrist — Adobe

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions.

Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials. Called Atlas, the platform is designed so that a trial sponsor can research what tools are available to measure things like physical activity or sleep for many commonly studied diseases. CEO Andy Coravos said that robust intelligence can help developers move more quickly and avoid mistakes that require costly changes to trial protocols.

Following the acquisition, HumanFirst will be another offering for Icon, which earned $8 billion last year running clinical trials for pharmaceutical companies and other related services. As of 2021, HumanFirst had raised $15 million in venture capital funding, and the decision to sell to Icon for an undisclosed amount comes as some big drug companies are reevaluating their approach to digital technologies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Medical records are filled with copy

focus

WSS

Marc Tessier

The mammogram wars are not over

As the dark side of IVF slowly comes into focus, even more transparency is needed

Continuity nursing helped my family in our darkest PICU moments

Duchenne breakthrough therapy leaves behind pioneering families

CDC: Cases of alpha

knowledge

fashion

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

Trump demands the U.S. pay no more for drugs than other countries … again

Activists slam private health insurers over coverage restrictions

Malaria cases in Florida and Texas: Here’s what you need to know

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The cancer drug shortage isn’t new — and neither are the solutions

Dobbs anniversary: the lost opportunity of abortion as health care

As the dark side of IVF slowly comes into focus, even more transparency is needed

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

BioMarin wins approval for gene therapy to treat hemophilia A

explore

Walensky prepares to leave CDC — and Congress — behind

Apple is now the first public company to be valued at $3 trillion

Medicare details structure of new drug price negotiation program

Tori Bowie and the unacceptable rates of Black maternal death

Marc Tessier

BioMarin wins approval for gene therapy to treat hemophilia A

hotspot

entertainment

focus

focus